特发性颅内压增高患者视盘体积、面积与Frisén评分的关系
本研究基于特发性颅内压增高治疗试验(IIHTT)的OCT亚组数据,回顾性分析126例患者基线与6、12个月时的视盘照相、OCT及Frisén评分。结果显示基线下视盘面积与OCT视神经头体积正相关(研究眼R²=0.77,P<.001),但乙酰唑胺治疗后两者相关性减弱,且Frisén评分与视盘面积、OCT体积无一致关系。结论提示Frisén评分不能反映治疗后视盘水肿的照相面积和OCT体积变化,临床用于监测疗效需谨慎。
要点
- 基线时视盘面积与OCT视神经头体积正相关(研究眼R²=0.77,P<.001)。
- 乙酰唑胺组6个月和12个月时面积与体积相关性弱于安慰剂组。
- 治疗后Frisén评分与视盘面积、OCT体积无一致关系。
核心结论
- Frisén评分不能反映乙酰唑胺治疗后视盘水肿的照相面积和OCT体积。
- 临床使用Frisén量表监测视盘水肿随时间变化需谨慎。
研究设计与样本
- 回顾性、非比较性分析随机对照试验数据(IIHTT)。
- 纳入IIHTT OCT亚组126例特发性颅内压增高伴轻度视力丧失患者。
- 基线和入组后6、12个月行视盘照相和OCT扫描。
- 训练有素的阅片者使用改良Frisén量表评分并测量视盘隆起面积,OCT评估视神经头体积。
主要发现
- 基线时视盘面积与OCT视神经头体积正相关(研究眼R²=0.77,P<.001)。
- 基线时治疗组间面积与体积相关性相似。
- 6个月时研究眼面积与体积相关性乙酰唑胺组R²=0.25,安慰剂组R²=0.76。
- 12个月时研究眼面积与体积相关性乙酰唑胺组R²=0.19,安慰剂组R²=0.65。
- 乙酰唑胺组6和12个月时Frisén评分与视盘面积、OCT体积无一致关系。
关键数值与推荐
- 基线研究眼视盘面积与OCT视神经头体积R²=0.77,P<.001。
- 6个月研究眼面积与体积R²:乙酰唑胺组0.25,安慰剂组0.76。
- 12个月研究眼面积与体积R²:乙酰唑胺组0.19,安慰剂组0.65。
临床怎么用
- 临床监测特发性颅内压增高患者视盘水肿治疗反应时,不宜仅依赖Frisén评分。
- 应结合OCT视神经头体积和视盘照相面积评估视盘水肿变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare measurements of papilledema using fundus photography, optical coherence tomography (OCT), and Frisén score in patients with idiopathic intracranial hypertension (IIH). DESIGN: Retrospective, noncomparative analysis of randomized controlled trial data. METHODS: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) evaluated weight management and treatment with acetazolamide compared with placebo in patients with IIH and mild visual loss. Among the 126 subjects in the IIHTT OCT substudy, fundus photographs and OCT scans of the optic disc were taken at baseline and at 6 and 12 months after enrollment. Trained readers scored each eye using a modified Frisén scale and measured the area of disc elevation. OCT scans assessed optic nerve head (ONH) volume. Correlations between volume and area were computed for both study and nonstudy eyes. RESULTS: Disc area and ONH volume were positively correlated at baseline (R2 = 0.77 in study eyes, P < .001). Correlations between area and volume were similar in the treatment groups at baseline, but were weaker in the acetazolamide group compared with the placebo group at 6 months (R2 = 0.25 vs R2 = 0.76 in study eyes) and 12 months (R2 = 0.19 vs R2 = 0.65 in study eyes). At 6 and 12 months after enrollment, there was no consistent relationship between Frisén score, disc area, and ONH volumes in the acetazolamide group. CONCLUSION: Frisén score fails to reflect the photographic area and OCT volume of papilledema after treatment with acetazolamide. Clinicians should use caution when using the Frisén scale to monitor the effect of treatment on papilledema over time.
引用
- Sheils CR, Fischer WS, Hollar RA, et al. The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension. Am J Ophthalmol. 2018. PMID: 30081012. doi:10.1016/j.ajo.2018.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。